Full-Time
Healthcare technology using AI for patient outcomes
$200k - $270k/yr
Expert
Company Historically Provides H1B Sponsorship
Chicago, IL, USA
The expected salary range is applicable if the role is performed from Illinois and may vary for other locations. Additionally, there are remote roles open to individuals in unincorporated Los Angeles.
Get referrals →
You have ways to get a Tempus referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 11 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Relocation Assistance
Company Equity
Performance Bonus
Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.
Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs.
Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine and patient care, announced the launch of the Tempus Advisory Board.
Illumina teams up with Tempus to expand DNA profiling beyond cancer.
Tempus exhibits 4 abstracts at the 2025 American College of Cardiology Annual Meeting.